J. Oates

5.2k citations

25 papers · 3.6k · 2 hit papers · h-index 14

Impact in

Gastroenterology top 0.5%
- Gastrointestinal Tumor Research and Treatment
Oncology top 1%
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments

Papers in

Oncology 21
- Colorectal Cancer Treatments and Studies 15
- Colorectal Cancer Surgical Treatments 9
- Colorectal Cancer Screening and Detection 3
Surgery 14
- Colorectal and Anal Carcinomas 8
- Esophageal Cancer Research and Treatment 4

Co-authors: David Cunningham (25 shared papers)A. Norman (7 shared papers)Timothy Iveson (4 shared papers)Naureen Starling (4 shared papers)Fareeda Y. Coxon (2 shared papers)M. Nicolson (2 shared papers)Sheela Rao (2 shared papers)Gary Middleton (3 shared papers)
Journals: Journal of Clinical Oncology (11 papers)European Journal of Cancer (3 papers)Annals of Oncology (3 papers)British Journal of Cancer (2 papers)International Journal of Radiation Oncology*Biology*Physics (1 paper)
Partner nations: United Kingdom Spain Sweden

In The Last Decade

J. Oates

25 papers receiving 3.5k citations

J. Oates's Hit Papers

align trajectories log scale

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer 2008 · 1.7k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2008 New England Journal of Medicine
1998 European Journal of Cancer

Peers

Countries citing papers authored by J. Oates

Since Specialization

Citations

This map shows the geographic impact of J. Oates's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Oates with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Oates more than expected).

Fields of papers citing papers by J. Oates

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Oates. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Oates. The network helps show where J. Oates may publish in the future.

Co-authors

The 25 scholars most cited alongside J. Oates, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Oates Line = papers co-authored together J. Oates links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer New England Journal of Medicine ·David Cunningham, Naureen Starling, Sheela Rao, Timothy Iveson, M. Nicolson, Fareeda Y. Coxon, Gary Middleton, Francis Daniel, J. Oates, A. Norman Hit paper breakdown →	2008	1727
2	Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? European Journal of Cancer ·Jervoise Andreyev, A. Norman, J. Oates, David Cunningham Hit paper breakdown →	1998	603
3	Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer Journal of Clinical Oncology ·Ian Chau, Gina Brown, David Cunningham, Diana Tait, Andrew Wotherspoon, A. Norman, Niall C. Tebbutt, Mark Hill, Paul J. Ross, Alison Massey, J. Oates	2006	324
4	Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C) Journal of Clinical Oncology ·Alice Dewdney, David Cunningham, Josep Tabernero, Jaume Capdevila, Bengt Glimelius, Andrés Cervantes, Diana Tait, Gina Brown, Andrew Wotherspoon, David González de Castro, Yu Jo Chua, Rachel Wong, Yolanda Barbáchano, J. Oates, Ian Chau	2012	287
5	Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group Journal of Clinical Oncology ·Naureen Starling, Sheela Rao, David Cunningham, Timothy Iveson, M. Nicolson, Fareeda Y. Coxon, Gary Middleton, Francis Daniel, J. Oates, A. Norman	2009	132
6	CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials British Journal of Cancer ·N. Maisey, A. Norman, A Hill, Alison Massey, J. Oates, David Cunningham	2005	125
7	A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer Annals of Oncology ·Paul J. Ross, A. Norman, David Cunningham, Andrew Webb, Timothy Iveson, Anwar R. Padhani, J Prendiville, Maggie Watson, Alison Massey, Răzvan Popescu, J. Oates	1997	107
8	Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial Journal of Clinical Oncology ·Alicia Okines, S. Ashley, David Cunningham, J. Oates, Andrea Turner, Janine Webb, Claire Saffery, Yu Jo Chua, Ian Chau	2010	104
9	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer Annals of Oncology ·Francesco Sclafani, Gina Brown, David Cunningham, Andrew Wotherspoon, Diana Tait, Clare Peckitt, Jessica Evans, Shun Yu, Larissa Mendes, Josep Tabernero, Bengt Glimelius, Andrés Cervantes, Janet Thomas, Ruwaida Begum, J. Oates, Ian Chau	2016	54
10	TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial JNCI Journal of the National Cancer Institute ·Francesco Sclafani, David González, David Cunningham, Sanna Hulkki Wilson, Clare Peckitt, Josep Tabernero, Bengt Glimelius, Andrés Cervantes, Alice Dewdney, Andrew Wotherspoon, Gina Brown, Diana Tait, J. Oates, Ian Chau	2014	37
11	A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma British Journal of Cancer ·Naureen Starling, Alicia Okines, David Cunningham, William Allum, Andrew Wotherspoon, Mgbeosuru Benson, J N Thompson, Janet Thomas, Gina Brown, Angela M. Riddell, Flora Stavridi, S. Ashley, J. Oates, Ian Chau	2009	20
12	Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer European Journal of Cancer ·Ian Chau, A. Norman, David Cunningham, Timothy Iveson, Mark Hill, Tamas Hickish, F. Lofts, Duncan I. Jodrell, Andrew Webb, Diana Tait, Paul J. Ross, P. Shellito, J. Oates	2005	18
13	Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial International Journal of Radiation OncologyBiologyPhysics ·Francesco Sclafani, Clare Peckitt, David Cunningham, Diana Tait, J. Giralt, Bengt Glimelius, Susana Roselló, Andrew Bateman, Tamas Hickish, Josep Tabernero, Janet Thomas, Gina Brown, J. Oates, Ian Chau	2015	18
14	Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in Assessing Prognosis and Predicting First-Line Treatment Efficacy in Follicular Lymphoma Patients Acta Haematologica ·Vincenzo Formica, A. Norman, David Cunningham, A. Wotherspoon, J. Oates, Gun Oh Chong	2009	13
15	305 Twelve weeks of neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation (CRT) and total mesorectal excision (TME) in MRI defined poor risk locally advanced rectal cancer resulted in promising tumour regression and rapid symptomatic relief European Journal of Cancer Supplements ·Ian Chau, David Cunningham, D. Tait, Gina Brown, Niall C. Tebbutt, Maureen V. Hill, Andrew Wotherspoon, Alyson Norman, Alison Massey, J. Oates	2003	9
16	FcγRIIaandFcγRIIIaPolymorphisms and Cetuximab Benefit in the Microscopic Disease Clinical Cancer Research ·Francesco Sclafani, David González de Castro, David Cunningham, Sanna Hulkki Wilson, Clare Peckitt, Jaume Capdevila, Bengt Glimelius, Susana Roselló, Andrew Wotherspoon, Gina Brown, Diana Tait, Ruwaida Begum, Janet Thomas, J. Oates, Ian Chau	2014	8
17	Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC). Journal of Clinical Oncology ·Francesco Sclafani, Clare Peckitt, David Cunningham, Jessica Evans, Gina Brown, Josep Tabernero, Bengt Glimelius, Andrés Cervantes, Diana Tait, Andrew Wotherspoon, Janet Thomas, J. Oates, Ian Chau	2014	5
18	Phase II trial evaluating capecitabine and irinotecan in patients (pts) with esophago-gastric (E-G) carcinoma having progressed or relapsed within 3 months of platinum-based chemotherapy Journal of Clinical Oncology ·L. Assersohn, A. Norman, Geoff Chong, Gina Brown, Paul J. Ross, C. Costello, L. Higgins, J. Oates, David Cunningham	2005	5
19	RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC). Journal of Clinical Oncology ·Francesco Sclafani, David González, David Cunningham, Sanna Hullki Wilson, Clare Peckitt, Josep Tabernero, Bengt Glimelius, Andrés Cervantes, Andrew Wotherspoon, Gina Brown, Diana Tait, J. Oates, Ian Chau	2014	3
20	HER-2 in high risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Journal of Clinical Oncology ·Francesco Sclafani, Amitesh Roy, Ian Chau, Andrew Wotherspoon, Clare Peckitt, Alice Dewdney, J. Oates, David Cunningham	2013	2

About J. Oates

J. Oates is a scholar working on Oncology, Surgery, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 25 papers that have together received 3.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (15 papers), Gastric Cancer Management and Outcomes (11 papers), Colorectal Cancer Surgical Treatments (9 papers), Colorectal and Anal Carcinomas (8 papers), Esophageal Cancer Research and Treatment (4 papers), Colorectal Cancer Screening and Detection (3 papers), Cancer Genomics and Diagnostics (2 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). The work is most often cited by research in Gastroenterology (587 citations), Oncology (2.1k citations), Pulmonary and Respiratory Medicine (1.9k citations), Surgery (1.7k citations) and Geriatrics and Gerontology (131 citations). J. Oates has collaborated with scholars based in United Kingdom, Spain and Sweden. Frequent co-authors include David Cunningham, A. Norman, Timothy Iveson, Naureen Starling, Fareeda Y. Coxon, M. Nicolson, Sheela Rao, Gary Middleton, Francis Daniel and A. Norman. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

J. Oates

Impact in

Papers in i

In The Last Decade

J. Oates

J. Oates's Hit Papers

Peers

Countries citing papers authored by J. Oates

Fields of papers citing papers by J. Oates

All Works

About J. Oates

Explore authors with similar magnitude of impact

Papers in